CD33-targeting extracellular vesicles deliver antisense oligonucleotides against FLT3-ITD and miR-125b for specific treatment of acute myeloid leukaemia.

Huan ChenMigara Kavishka JayasingheEric Yew Meng YeoZhiyuan WuMarco PirisinuWaqas Muhammad UsmanThach Tuan PhamKah Wai LimNhan Van TranAnskar Y H LeungXin DuQiaoxia ZhangAnh Tuân PhanMinh T N Le

Published in: Cell proliferation (2022)

Targeted RBCEVs represent an innovative, efficient, and versatile delivery platform for therapeutic ASOs and can expedite the clinical translation of oligonucleotide drugs for AML treatments by overcoming current obstacles in oligonucleotide delivery.

Keyphrases

acute myeloid leukemia
cancer therapy
allogeneic hematopoietic stem cell transplantation
liver failure
drug induced
nucleic acid
bone marrow
high throughput
tyrosine kinase
hepatitis b virus
intensive care unit
combination therapy
drug delivery
immune response